No announcement yet.

WISCONSIN: Step Therapy Advocacy Day (Mar 6)

  • Filter
  • Time
  • Show
Clear All
new posts

  • WISCONSIN: Step Therapy Advocacy Day (Mar 6)

    Wisconsin Step Therapy Advocacy Day

    Wednesday, March 6, 2019
    9:00 AM - 3:00 PM
    Wisconsin State Capitol
    2 East Main Street
    Hearing Room 300 NE
    Madison, WI 53702

    The Wisconsin Step Therapy Coalition invites you to join us on this important day to meet with your state legislators and discuss step therapy legislation. The day will begin with a briefing in the morning followed by legislative visits in the afternoon.

    Please register by February 20 at

    If you have any questions, please contact:
    Kari Lato at or Angie Thies at

    What is step therapy?

    Step Therapy—Clinical Algorithms, Legislation, and Optimal Prescribing
    Michael A. Fischer, MD, Jerry Avorn, MD

    JAMA. 2017;317(8):801-802. doi:10.1001/jama.2016.20619

    Increasing prescription drug costs impose economic burdens for patients and payers and are reflected in substantial increases in insurance premiums for individuals and employers and budget stress for public programs. One widely used approach to control prescription costs is “step therapy”: requiring patients to try a less expensive drug for a given condition before a more expensive option can be approved. Authorization of the second-line agent may require attestation by the prescriber that the patient took the initial medication and had adverse effects or inadequate clinical benefit. Such clinical algorithms are often sensible and evidence based and can improve the quality of care. But sometimes they are not, because of limited evidence, inadequate attention to the underlying evidence, or an emphasis on cost containment rather than patient outcomes. The economic stakes can be high, because manufacturers’ promotion to both prescribers and patients is usually aimed at encouraging use of more costly second-line agents.
    Dave Bexfield

  • #2
    FYI, there is more and more evidence that step therapy may not be the smartest approach in MS, as research is showing that stronger meds at the outset leads to better control of the disease (and potentially lower cost for insurance companies).
    Dave Bexfield